Droxidopa is primarily used in the treatment of neurogenic orthostatic hypotension (NOH), a condition characterized by a significant drop in blood pressure upon standing, leading to dizziness, lightheadedness, and fainting. It works by being converted into norepinephrine in the body, which helps to constrict blood vessels and increase blood pressure, thereby alleviating symptoms associated with NOH. This makes it particularly beneficial for patients with conditions like Parkinson’s disease, multiple system atrophy, and pure autonomic failure, where NOH is a common complication. Additionally, droxidopa has been explored for its potential in improving mobility and reducing the risk of falls in elderly patients with NOH. Its ability to enhance norepinephrine levels also suggests possible applications in addressing fatigue and cognitive symptoms in certain neurological disorders, though these uses are still under investigation.